- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
- Interventions
- Tirzepatide, Standard medical treatment
- Drug · Other
- Lead sponsor
- Alaa Sada
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 311
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Critically Ill, Hypoglycemia
- Interventions
- Glucagon-Like Peptide-1, Saline
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide 2 MG, Dapagliflozin 10 MG
- Drug
- Lead sponsor
- Consano Clinical Research, LLC
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Shavano Park, Texas
- Conditions
- Obstructive Sleep Apnea, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Riverside, California • Brandon, Florida • Ocala, Florida + 15 more
- Conditions
- Obesity
- Interventions
- Medically tailored meals, Noom®, Usual care
- Other · Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Congenital Hyperinsulinism
- Interventions
- dasiglucagon, Placebo
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 7 Days to 364 Days
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Fort Worth, Texas
- Conditions
- Atrial Fibrillation
- Interventions
- Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation
- Drug · Other · Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hyperglycemia Drug Induced
- Interventions
- REMD-477
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes
- Interventions
- Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin glargine, Liraglutide, Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 978 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Eden Prairie, Minnesota
- Conditions
- Type2Diabetes, ASCVD
- Interventions
- SGLT2 inhibitor, GLP-1 receptor agonist
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 36
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
- Conditions
- Alcohol Use Disorder (AUD)
- Interventions
- Pemvidutide, Placebo
- Drug · Other
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more
- Conditions
- Diabetes
- Interventions
- Gut motility quantification using a capsule after initiating GLP-1RA therapy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Type2 Diabetes, Kidney Diseases
- Interventions
- Exenatide Extended Release for Inj Susp 2 MG, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- G-Pen Mini™ (glucagon injection), Glucose Tablets
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
- Conditions
- Obesity, Overweight
- Interventions
- Cagrilintide, Placebo (matched to Cagrilintide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 11
- States / cities
- Walnut Creek, California • Fleming Island, Florida • Jacksonville, Florida + 8 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec/liraglutide, liraglutide, exenatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Mesa, Arizona + 73 more
- Conditions
- Muscle Composition, Obesity, Quality of Life (QOL)
- Interventions
- Resistance Exercise, GLP-1 RAs
- Behavioral · Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Obesity & Overweight
- Interventions
- Remote Monitoring Program
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Type 1 Diabetes
- Interventions
- Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Lixisenatide (AVE0010), Placebo, Pen auto-injector, Pioglitazone, Metformin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more
- Conditions
- Binge-Eating Disorder
- Interventions
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml, Placebo
- Drug
- Lead sponsor
- Kelly Allison
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania